Drugs / Rituximab and Hyaluronidase Human
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07220187 Background | Aug 2026 → Oct 2035 expected | Richter transformation | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab and Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220187 ↗ |
| Route | Subcutaneous | “Given SC” NCT07220187 ↗ |